Clinical trial approval / initiation

Explore the landscape of Clinical trial approval / initiation in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Clinical trial approval / initiation to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery
CompanyDeals

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery

Roche (SWX: ROP; OTCMKTS: RHHBY) announced an exclusive worldwide licensing agreement with Rona Therapeutics to develop an investigational RNA interference (RNAi) candidate targeting activin receptor‑like kinase 7 (ALK7), built on…

Sinocelltech's SCT810 Injection Wins NMPA Clearance for Phase I/II Study – Anti‑TFPI Antibody Offers Factor‑Independent Prophylaxis for Hemophilia A and B With or Without Inhibitors

Sinocelltech’s SCT810 Injection Wins NMPA Clearance for Phase I/II Study – Anti‑TFPI Antibody Offers Factor‑Independent Prophylaxis for Hemophilia A and B With or Without Inhibitors

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

HuidaGene Receives CDE IND Approval for Ophthalmology Gene Therapy HG004

CompanyDrug

Neurophth Biotechnology Receives NMPA Approval for Phase I/II Gene Therapy Study

CompanyDrug

CanSino Biologics Receives NMPA Approval for Bivalent COVID-19 mRNA Vaccine

CompanyDrug

JS InnoPharm Initiates Phase Ib Study of AURKA Inhibitor VIC-1911 for EGFR-TKI Resistant NSCLC

CompanyDrug

AffaMed Therapeutics Gets NMPA Approval for Phase III Dextenza Study in Post-Ophthalmic Surgery

CompanyDrug

Junshi Biosciences’ JS401 Receives NMPA Approval for Hyperlipidemia Clinical Trial

CompanyDrug

Aosaikang Pharmaceutical Receives NMPA Review for ASKC200 Liniment from Propella Therapeutics

CompanyDrug

Chengdu Hyperway Pharmaceuticals’ HBW-004285 Gets NMPA Tacit Approval for Pain Treatment

Show More